LBP-AOT: Action Observation Training in Patients With Chronic Low Back Pain

Sponsor
Istituto Clinico Humanitas (Other)
Overall Status
Withdrawn
CT.gov ID
NCT04157374
Collaborator
(none)
0
1
2
38
0

Study Details

Study Description

Brief Summary

The study is a single-blind controlled randomized clinical trial.

Condition or Disease Intervention/Treatment Phase
  • Other: Action Observation training
  • Other: Active Exercises
N/A

Detailed Description

Patients will be recruited and then randomly assigned by an external collaborator to the experimental group or to the control group. To the patients that belong to the experimental group will be asked to watch a video showing a person carrying out some exercises (12 exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional) and then they will have to practice them.On the other hand, to the patients that belong to the control group will be given a brochure with the same exercises the patients of the experimental group received through the video. Both groups will have to watch the video or read the brochure and repeat the exercises 5 times per week for 3 weeks. Patients will be evaluated before the treatment (T0), three weeks after the beginning (T1) and 4 months upon the end of it (T2). The evaluation will consist in the administration of the Oswestry Disability Index, of the Tampa Scale of Kinesiophobia, of the Numerical Rating Scale and of the Medical Outcomes Study Short Form 36.

A physiotherapist will instruct the patients about the exercises while a second one blinded about the belonging group of patients, will administer the evaluation scales.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Action Observation Training in Patients With Chronic Low Back Pain
Actual Study Start Date :
May 29, 2019
Actual Primary Completion Date :
Jan 10, 2021
Anticipated Study Completion Date :
Jul 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: EXPERIMENTAL GROUP

AOT and Active exercises

Other: Action Observation training
They have to watch a video showing a person carrying out exercises (12 exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional). then they have to practice them. The observation of the exercises and their performance last 8 minutes (4 minutes for observation and 4 minutes for practice). They have to repeat the exercises 5 times per week for 3 weeks.
Other Names:
  • AOT
  • Other: Active Exercises
    Execution of exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional activity. Patients of the control group recieve a brochure with the same exercises the patients of the experimental group received through the video. They will be asked to read the exercise 3 times and to practice it for 4 minutes. They have to repeat the exercises 5 times per week for 3 weeks.

    Active Comparator: Control group

    Active exercises

    Other: Active Exercises
    Execution of exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional activity. Patients of the control group recieve a brochure with the same exercises the patients of the experimental group received through the video. They will be asked to read the exercise 3 times and to practice it for 4 minutes. They have to repeat the exercises 5 times per week for 3 weeks.

    Outcome Measures

    Primary Outcome Measures

    1. Change of disability of patients [Patients will be evaluated before the treatment (T0), three weeks after the beginning (T1) and 4 months upon the end of it (T2)]

      Change in Oswestry Disability Index (ODI-I). Range: 0 (lower disability), 50 (higher disability)

    Secondary Outcome Measures

    1. Pain of patients [Patients will be evaluated before the treatment (T0), three weeks after the beginning (T1) and 4 months upon the end of it (T2)]

      Numeric rating Scale (NRS), Range: 0 (no pain), 10 (maximum pain)

    2. Quality of life of patients [Patients will be evaluated before the treatment (T0), three weeks after the beginning (T1) and 4 months upon the end of it (T2)]

      Short form 36.36 Items divided in 8 sub-scales. Each of the 8 summed scores is linearly transformed onto a scale from 0 (negative health) to 100 (positive health) to provide a score for each subscale. Each subscale is used indipendently.

    3. fear of movement of patients [Patients will be evaluated before the treatment (T0), three weeks after the beginning (T1) and 4 months upon the end of it (T2)]

      TAMPA Scale of kinesiophobia, Range: 13 (minimum level of kinesiophobia)- 52 (maximum level of kinesiophobia).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    65 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients with chronic aspecific LBP (documented story of more than 12 week-long symptomatology)

    • Good understanding of Italian language

    • Aged over 65

    Exclusion Criteria:
    • Severe sight or hearing impairement

    • Cognitive deficit (assessed by a Mini Mental State Examination score ≤21 [14]).

    • Specific LBP (previous spine surgery, deformation, infection, fracture, malignant tumor, general disorders or neuromuscular pathologies)

    • Patients who previously experimented AOT

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Roberto Gatti Rozzano Milan Italy 20089

    Sponsors and Collaborators

    • Istituto Clinico Humanitas

    Investigators

    None specified.

    Study Documents (Full-Text)

    More Information

    Publications

    None provided.
    Responsible Party:
    Michele Tedeschi, Head of Physiotherapy, Istituto Clinico Humanitas
    ClinicalTrials.gov Identifier:
    NCT04157374
    Other Study ID Numbers:
    • CLF19/01
    First Posted:
    Nov 8, 2019
    Last Update Posted:
    Sep 16, 2021
    Last Verified:
    Sep 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 16, 2021